APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mucopolysaccharidosis Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Mucopolysaccharidosis Therapeutics Market Analysis and Forecast 2026-2032

2 January 2026198 pages

Choose your research edition.

Industry ResearchMucopolysaccharidosis Therapeutics Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Mucopolysaccharidosis Therapeutics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Mucopolysaccharidosis Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mucopolysaccharidosis Therapeutics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Mucopolysaccharidosis Therapeutics Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Mucopolysaccharidosis Therapeutics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Mucopolysaccharidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Mucopolysaccharidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Mucopolysaccharidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Mucopolysaccharidosis Therapeutics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Mucopolysaccharidosis Therapeutics include Abeona Therapeutics Inc., ArmaGen, BioMarin, Denali Therapeutics, Genzyme Corporation, Lysogene, REGENXBIO Inc., Sangamo Therapeutics and Shire (Takeda Pharmaceutical Company Limited), etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Mucopolysaccharidosis Therapeutics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Mucopolysaccharidosis Therapeutics, also provides the revenue of main regions and countries. Of the upcoming market potential for Mucopolysaccharidosis Therapeutics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Mucopolysaccharidosis Therapeutics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Mucopolysaccharidosis Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Mucopolysaccharidosis Therapeutics revenue, projected growth trends, production technology, application and end-user industry.

Mucopolysaccharidosis Therapeutics Segment by Company

Abeona Therapeutics Inc.

ArmaGen

BioMarin

Denali Therapeutics

Genzyme Corporation

Lysogene

REGENXBIO Inc.

Sangamo Therapeutics

Shire (Takeda Pharmaceutical Company Limited)

Ultragenyx Pharmaceutical

Mucopolysaccharidosis Therapeutics Segment by Type

Intravenous

Intracerebroventricular (ICV)

Mucopolysaccharidosis Therapeutics Segment by Application

Hospital

Clinic

Other

Mucopolysaccharidosis Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mucopolysaccharidosis Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mucopolysaccharidosis Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mucopolysaccharidosis Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Mucopolysaccharidosis Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Mucopolysaccharidosis Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Mucopolysaccharidosis Therapeutics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Intravenous Major Player Table 3. Intracerebroventricular (ICV) Major Player Table 4. Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Player Table 6. Clinic Major Player Table 7. Other Major Player Table 8. Mucopolysaccharidosis Therapeutics Industry Trends Table 9. Mucopolysaccharidosis Therapeutics Industry Drivers Table 10. Mucopolysaccharidosis Therapeutics Industry Opportunities and Challenges Table 11. Mucopolysaccharidosis Therapeutics Industry Restraints Table 12. Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Mucopolysaccharidosis Therapeutics Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Mucopolysaccharidosis Therapeutics Market Share by Region (2021-2026) Table 15. Global Mucopolysaccharidosis Therapeutics Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Mucopolysaccharidosis Therapeutics Market Share by Region (2027-2032) Table 17. Global Mucopolysaccharidosis Therapeutics Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Players (2021-2026) Table 19. Global Mucopolysaccharidosis Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Mucopolysaccharidosis Therapeutics Key Players Headquarters & Area Served Table 21. Global Mucopolysaccharidosis Therapeutics Players, Product Type & Application Table 22. Global Mucopolysaccharidosis Therapeutics Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Mucopolysaccharidosis Therapeutics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Mucopolysaccharidosis Therapeutics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2021-2026) Table 29. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2027-2032) Table 30. Global Mucopolysaccharidosis Therapeutics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2021-2026) Table 34. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2027-2032) Table 35. Abeona Therapeutics Inc. Company Information Table 36. Abeona Therapeutics Inc. Business Overview Table 37. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Portfolio Table 39. Abeona Therapeutics Inc. Recent Development Table 40. ArmaGen Company Information Table 41. ArmaGen Business Overview Table 42. ArmaGen Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. ArmaGen Mucopolysaccharidosis Therapeutics Product Portfolio Table 44. ArmaGen Recent Development Table 45. BioMarin Company Information Table 46. BioMarin Business Overview Table 47. BioMarin Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. BioMarin Mucopolysaccharidosis Therapeutics Product Portfolio Table 49. BioMarin Recent Development Table 50. Denali Therapeutics Company Information Table 51. Denali Therapeutics Business Overview Table 52. Denali Therapeutics Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Portfolio Table 54. Denali Therapeutics Recent Development Table 55. Genzyme Corporation Company Information Table 56. Genzyme Corporation Business Overview Table 57. Genzyme Corporation Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Portfolio Table 59. Genzyme Corporation Recent Development Table 60. Lysogene Company Information Table 61. Lysogene Business Overview Table 62. Lysogene Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Lysogene Mucopolysaccharidosis Therapeutics Product Portfolio Table 64. Lysogene Recent Development Table 65. REGENXBIO Inc. Company Information Table 66. REGENXBIO Inc. Business Overview Table 67. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Portfolio Table 69. REGENXBIO Inc. Recent Development Table 70. Sangamo Therapeutics Company Information Table 71. Sangamo Therapeutics Business Overview Table 72. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Portfolio Table 74. Sangamo Therapeutics Recent Development Table 75. Shire (Takeda Pharmaceutical Company Limited) Company Information Table 76. Shire (Takeda Pharmaceutical Company Limited) Business Overview Table 77. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Portfolio Table 79. Shire (Takeda Pharmaceutical Company Limited) Recent Development Table 80. Ultragenyx Pharmaceutical Company Information Table 81. Ultragenyx Pharmaceutical Business Overview Table 82. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Portfolio Table 84. Ultragenyx Pharmaceutical Recent Development Table 85. North America Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 86. North America Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 87. North America Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 88. North America Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 89. North America Mucopolysaccharidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Mucopolysaccharidosis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Mucopolysaccharidosis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 92. Europe Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 93. Europe Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 94. Europe Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 95. Europe Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 96. Europe Mucopolysaccharidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Mucopolysaccharidosis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 98. Europe Mucopolysaccharidosis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 99. China Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 100. China Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 101. China Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 102. China Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 104. Asia Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 105. Asia Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 106. Asia Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Mucopolysaccharidosis Therapeutics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia Mucopolysaccharidosis Therapeutics Revenue by Region (US$ Million) & (2021-2026) Table 109. Asia Mucopolysaccharidosis Therapeutics Revenue by Region (US$ Million) & (2027-2032) Table 110. SAMEA Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026) & (US$ Million) Table 111. SAMEA Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032) & (US$ Million) Table 112. SAMEA Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026) & (US$ Million) Table 113. SAMEA Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032) & (US$ Million) Table 114. SAMEA Mucopolysaccharidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. SAMEA Mucopolysaccharidosis Therapeutics Revenue by Country (2021-2026) & (US$ Million) Table 116. SAMEA Mucopolysaccharidosis Therapeutics Revenue by Country (US$ Million) & (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Mucopolysaccharidosis Therapeutics Image Figure 2. Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mucopolysaccharidosis Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 4. Intravenous Image Figure 5. Intracerebroventricular (ICV) Image Figure 6. Global Mucopolysaccharidosis Therapeutics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Mucopolysaccharidosis Therapeutics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Other Image Figure 11. Global Mucopolysaccharidosis Therapeutics Market Size (US$ Million) & (2021-2032) Figure 12. Global Mucopolysaccharidosis Therapeutics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Mucopolysaccharidosis Therapeutics Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Mucopolysaccharidosis Therapeutics Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Mucopolysaccharidosis Therapeutics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Mucopolysaccharidosis Therapeutics Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2021-2032) Figure 19. Global Mucopolysaccharidosis Therapeutics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2021-2032) Figure 22. North America Mucopolysaccharidosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Mucopolysaccharidosis Therapeutics Revenue Share by Type (2021-2032) Figure 24. North America Mucopolysaccharidosis Therapeutics Revenue Share by Application (2021-2032) Figure 25. North America Mucopolysaccharidosis Therapeutics Revenue Share by Country (2021-2032) Figure 26. United States Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Mucopolysaccharidosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Mucopolysaccharidosis Therapeutics Revenue Share by Type (2021-2032) Figure 31. Europe Mucopolysaccharidosis Therapeutics Revenue Share by Application (2021-2032) Figure 32. Europe Mucopolysaccharidosis Therapeutics Revenue Share by Country (2021-2032) Figure 33. Germany Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Mucopolysaccharidosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Mucopolysaccharidosis Therapeutics Revenue Share by Type (2021-2032) Figure 43. China Mucopolysaccharidosis Therapeutics Revenue Share by Application (2021-2032) Figure 44. Asia Mucopolysaccharidosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Mucopolysaccharidosis Therapeutics Revenue Share by Type (2021-2032) Figure 46. Asia Mucopolysaccharidosis Therapeutics Revenue Share by Application (2021-2032) Figure 47. Asia Mucopolysaccharidosis Therapeutics Revenue Share by Region (2021-2032) Figure 48. Japan Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Mucopolysaccharidosis Therapeutics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Mucopolysaccharidosis Therapeutics Revenue Share by Type (2021-2032) Figure 56. SAMEA Mucopolysaccharidosis Therapeutics Revenue Share by Application (2021-2032) Figure 57. SAMEA Mucopolysaccharidosis Therapeutics Revenue Share by Country (2021-2032) Figure 58. Brazil Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Mucopolysaccharidosis Therapeutics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Intravenous
  • Intracerebroventricular (ICV)
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Abeona Therapeutics Inc.
  • ArmaGen
  • BioMarin
  • Denali Therapeutics
  • Genzyme Corporation
  • Lysogene
  • REGENXBIO Inc.
  • Sangamo Therapeutics
  • Shire (Takeda Pharmaceutical Company Limited)
  • Ultragenyx Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Mucopolysaccharidosis Therapeutics Market by Type
  3. 1.2.1 Global Mucopolysaccharidosis Therapeutics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Intravenous
  5. 1.2.3 Intracerebroventricular (ICV)
  6. 1.3 Mucopolysaccharidosis Therapeutics Market by Application
  7. 1.3.1 Global Mucopolysaccharidosis Therapeutics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Mucopolysaccharidosis Therapeutics Market Dynamics
  1. 2.1 Mucopolysaccharidosis Therapeutics Industry Trends
  2. 2.2 Mucopolysaccharidosis Therapeutics Industry Drivers
  3. 2.3 Mucopolysaccharidosis Therapeutics Industry Opportunities and Challenges
  4. 2.4 Mucopolysaccharidosis Therapeutics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Mucopolysaccharidosis Therapeutics Market Perspective (2021-2032)
  2. 3.2 Global Mucopolysaccharidosis Therapeutics Growth Trends by Region
  3. 3.2.1 Global Mucopolysaccharidosis Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Mucopolysaccharidosis Therapeutics Market Size by Region (2021-2026)
  5. 3.2.3 Global Mucopolysaccharidosis Therapeutics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Mucopolysaccharidosis Therapeutics Revenue by Players
  2. 4.1.1 Global Mucopolysaccharidosis Therapeutics Revenue by Players (2021-2026)
  3. 4.1.2 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Mucopolysaccharidosis Therapeutics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Mucopolysaccharidosis Therapeutics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Mucopolysaccharidosis Therapeutics Key Players Headquarters & Area Served
  7. 4.4 Global Mucopolysaccharidosis Therapeutics Players, Product Type & Application
  8. 4.5 Global Mucopolysaccharidosis Therapeutics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Mucopolysaccharidosis Therapeutics Market CR5 and HHI
  11. 4.6.3 2025 Mucopolysaccharidosis Therapeutics Tier 1, Tier 2, and Tier 3
5 Mucopolysaccharidosis Therapeutics Market Size by Type
  1. 5.1 Global Mucopolysaccharidosis Therapeutics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2032)
  3. 5.3 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Type (2021-2032)
6 Mucopolysaccharidosis Therapeutics Market Size by Application
  1. 6.1 Global Mucopolysaccharidosis Therapeutics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2032)
  3. 6.3 Global Mucopolysaccharidosis Therapeutics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Abeona Therapeutics Inc.
  2. 7.1.1 Abeona Therapeutics Inc. Company Information
  3. 7.1.2 Abeona Therapeutics Inc. Business Overview
  4. 7.1.3 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Abeona Therapeutics Inc. Mucopolysaccharidosis Therapeutics Product Portfolio
  6. 7.1.5 Abeona Therapeutics Inc. Recent Developments
  7. 7.2 ArmaGen
  8. 7.2.1 ArmaGen Company Information
  9. 7.2.2 ArmaGen Business Overview
  10. 7.2.3 ArmaGen Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 ArmaGen Mucopolysaccharidosis Therapeutics Product Portfolio
  12. 7.2.5 ArmaGen Recent Developments
  13. 7.3 BioMarin
  14. 7.3.1 BioMarin Company Information
  15. 7.3.2 BioMarin Business Overview
  16. 7.3.3 BioMarin Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 BioMarin Mucopolysaccharidosis Therapeutics Product Portfolio
  18. 7.3.5 BioMarin Recent Developments
  19. 7.4 Denali Therapeutics
  20. 7.4.1 Denali Therapeutics Company Information
  21. 7.4.2 Denali Therapeutics Business Overview
  22. 7.4.3 Denali Therapeutics Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Denali Therapeutics Mucopolysaccharidosis Therapeutics Product Portfolio
  24. 7.4.5 Denali Therapeutics Recent Developments
  25. 7.5 Genzyme Corporation
  26. 7.5.1 Genzyme Corporation Company Information
  27. 7.5.2 Genzyme Corporation Business Overview
  28. 7.5.3 Genzyme Corporation Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Genzyme Corporation Mucopolysaccharidosis Therapeutics Product Portfolio
  30. 7.5.5 Genzyme Corporation Recent Developments
  31. 7.6 Lysogene
  32. 7.6.1 Lysogene Company Information
  33. 7.6.2 Lysogene Business Overview
  34. 7.6.3 Lysogene Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lysogene Mucopolysaccharidosis Therapeutics Product Portfolio
  36. 7.6.5 Lysogene Recent Developments
  37. 7.7 REGENXBIO Inc.
  38. 7.7.1 REGENXBIO Inc. Company Information
  39. 7.7.2 REGENXBIO Inc. Business Overview
  40. 7.7.3 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 REGENXBIO Inc. Mucopolysaccharidosis Therapeutics Product Portfolio
  42. 7.7.5 REGENXBIO Inc. Recent Developments
  43. 7.8 Sangamo Therapeutics
  44. 7.8.1 Sangamo Therapeutics Company Information
  45. 7.8.2 Sangamo Therapeutics Business Overview
  46. 7.8.3 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sangamo Therapeutics Mucopolysaccharidosis Therapeutics Product Portfolio
  48. 7.8.5 Sangamo Therapeutics Recent Developments
  49. 7.9 Shire (Takeda Pharmaceutical Company Limited)
  50. 7.9.1 Shire (Takeda Pharmaceutical Company Limited) Company Information
  51. 7.9.2 Shire (Takeda Pharmaceutical Company Limited) Business Overview
  52. 7.9.3 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Shire (Takeda Pharmaceutical Company Limited) Mucopolysaccharidosis Therapeutics Product Portfolio
  54. 7.9.5 Shire (Takeda Pharmaceutical Company Limited) Recent Developments
  55. 7.10 Ultragenyx Pharmaceutical
  56. 7.10.1 Ultragenyx Pharmaceutical Company Information
  57. 7.10.2 Ultragenyx Pharmaceutical Business Overview
  58. 7.10.3 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Ultragenyx Pharmaceutical Mucopolysaccharidosis Therapeutics Product Portfolio
  60. 7.10.5 Ultragenyx Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Mucopolysaccharidosis Therapeutics Revenue (2021-2032)
  2. 8.2 North America Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2032)
  3. 8.2.1 North America Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026)
  4. 8.2.2 North America Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032)
  5. 8.3 North America Mucopolysaccharidosis Therapeutics Revenue Share by Type (2021-2032)
  6. 8.4 North America Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2032)
  7. 8.4.1 North America Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026)
  8. 8.4.2 North America Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032)
  9. 8.5 North America Mucopolysaccharidosis Therapeutics Revenue Share by Application (2021-2032)
  10. 8.6 North America Mucopolysaccharidosis Therapeutics Revenue by Country
  11. 8.6.1 North America Mucopolysaccharidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Mucopolysaccharidosis Therapeutics Revenue by Country (2021-2026)
  13. 8.6.3 North America Mucopolysaccharidosis Therapeutics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Mucopolysaccharidosis Therapeutics Revenue (2021-2032)
  2. 9.2 Europe Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2032)
  3. 9.2.1 Europe Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026)
  4. 9.2.2 Europe Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032)
  5. 9.3 Europe Mucopolysaccharidosis Therapeutics Revenue Share by Type (2021-2032)
  6. 9.4 Europe Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2032)
  7. 9.4.1 Europe Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026)
  8. 9.4.2 Europe Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032)
  9. 9.5 Europe Mucopolysaccharidosis Therapeutics Revenue Share by Application (2021-2032)
  10. 9.6 Europe Mucopolysaccharidosis Therapeutics Revenue by Country
  11. 9.6.1 Europe Mucopolysaccharidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Mucopolysaccharidosis Therapeutics Revenue by Country (2021-2026)
  13. 9.6.3 Europe Mucopolysaccharidosis Therapeutics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Mucopolysaccharidosis Therapeutics Revenue (2021-2032)
  2. 10.2 China Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2032)
  3. 10.2.1 China Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026)
  4. 10.2.2 China Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032)
  5. 10.3 China Mucopolysaccharidosis Therapeutics Revenue Share by Type (2021-2032)
  6. 10.4 China Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2032)
  7. 10.4.1 China Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026)
  8. 10.4.2 China Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032)
  9. 10.5 China Mucopolysaccharidosis Therapeutics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Mucopolysaccharidosis Therapeutics Revenue (2021-2032)
  2. 11.2 Asia Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2032)
  3. 11.2.1 Asia Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026)
  4. 11.2.2 Asia Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032)
  5. 11.3 Asia Mucopolysaccharidosis Therapeutics Revenue Share by Type (2021-2032)
  6. 11.4 Asia Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2032)
  7. 11.4.1 Asia Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026)
  8. 11.4.2 Asia Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032)
  9. 11.5 Asia Mucopolysaccharidosis Therapeutics Revenue Share by Application (2021-2032)
  10. 11.6 Asia Mucopolysaccharidosis Therapeutics Revenue by Country
  11. 11.6.1 Asia Mucopolysaccharidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Mucopolysaccharidosis Therapeutics Revenue by Country (2021-2026)
  13. 11.6.3 Asia Mucopolysaccharidosis Therapeutics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Mucopolysaccharidosis Therapeutics Revenue (2021-2032)
  2. 12.2 SAMEA Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Mucopolysaccharidosis Therapeutics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Mucopolysaccharidosis Therapeutics Revenue by Type (2027-2032)
  5. 12.3 SAMEA Mucopolysaccharidosis Therapeutics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Mucopolysaccharidosis Therapeutics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Mucopolysaccharidosis Therapeutics Revenue by Application (2027-2032)
  9. 12.5 SAMEA Mucopolysaccharidosis Therapeutics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Mucopolysaccharidosis Therapeutics Revenue by Country
  11. 12.6.1 SAMEA Mucopolysaccharidosis Therapeutics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Mucopolysaccharidosis Therapeutics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Mucopolysaccharidosis Therapeutics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst